Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The glial glutamate transporter EAAT2 is primarily responsible for clearance of glutamate from the synaptic cleft and loss of EAAT2 has been previously reported in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The loss of functional EAAT2 could lead to the accumulation of extracellular glutamate, resulting in cell death known as excitotoxicity. However, it is still unknown whether it is a primary cause in the cascade leading to neuron degeneration or a secondary event to cell death. The goals of this study were to generate transgenic mice overexpressing EAAT2 and then to cross these mice with the ALS-associated mutant SOD1(G93A) mice to investigate whether supplementation of the loss of EAAT2 would delay or rescue the disease progression. We show that the amount of EAAT2 protein and the associated Na+-dependent glutamate uptake was increased about 2-fold in our EAAT2 transgenic mice. The transgenic EAAT2 protein was properly localized to the cell surface on the plasma membrane. Increased EAAT2 expression protects neurons from L-glutamate induced cytotoxicity and cell death in vitro. Furthermore, our EAAT2/G93A double transgenic mice showed a statistically significant (14 days) delay in grip strength decline but not in the onset of paralysis, body weight decline or life span when compared with G93A littermates. Moreover, a delay in the loss of motor neurons and their axonal morphologies as well as other events including caspase-3 activation and SOD1 aggregation were also observed. These results suggest that the loss of EAAT2 may contribute to, but does not cause, motor neuron degeneration in ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Epilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., Iwama, H., Nishikawa, T., Ichihara, N., Kikuchi, T., et al. (1997) · Science · doi:10.1126/science.276.5319.1699 · Cited by 1,752
Localization of neuronal and glial glutamate transporters
Rothstein, J. D., Martin, L., Levey, A. I., Dykes-Hoberg, M., Jin, L., Wu, D., Nash, N., & Kuncl, R. W. (1994) · Neuron · doi:10.1016/0896-6273(94)90038-8 · Cited by 1,702
Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,445
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341
Koh, J. Y., & Choi, D. W. (1987) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(87)90041-0 · Cited by 1,260
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,228
Cited by
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
“Genetic overexpression of transporters in transgenic mice and in engineered cell lines suggest that increasing the density of transporter in astroglia can be neuroprotectiv”
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Mechanisms of Disease: astrocytes in neurodegenerative disease
Maragakis, N. J., & Rothstein, J. D. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0355 · Cited by 812
Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?
Lewerenz, J., & Maher, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00469 · Cited by 718
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 594
Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis
Van Den Bosch, L., Van Damme, P., Bogaert, E., & Robberecht, W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.002 · Cited by 491
Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury
Yi, J.-H., & Hazell, A. S. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.001 · Cited by 479
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
“The resulting extracellular accumulation of glutamate has been proposed to lead to motor neuron death through excitotoxicity (Rothstein et al. 1992, 1995; Howland et al. 2002; Guo et al. 2003; Pardo et al. 2006).”
Kim, K., Lee, S., Kegelman, T. P., Su, Z., Das, S. K., Dash, R., Dasgupta, S., Barral, P. M., Hedvat, M., Diaz, P., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22609 · Cited by 395
Neuroinflammation and regulation of glial glutamate uptake in neurological disorders
Tilleux, S., & Hermans, E. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21325 · Cited by 381
Liu, J., & Wang, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01005 · Cited by 376
“Guo et al. observed a delay in MN degeneration and disease progression in transgenic mSOD1 mice overexpressing EAAT2 (27), suggesting the loss of EAAT2 contributes to MN degeneration in ALS.”
InfluentialMiller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
“Levels of ambient, extracellular glutamate are tightly regulated by glutamate transporters especially EAAT2 (GLT-1), which is highly expressed on glial cells (Rothstein et al., 1996; Guo et al., 2003).”
Glutamate transporters: animal models to neurologic disease
Maragakis, N. J., & Rothstein, J. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.007 · Cited by 352
Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
Regan, M. R., Huang, Y. H., Kim, Y. S., Dykes-Hoberg, M. I., Jin, L., Watkins, A. M., Bergles, D. E., & Rothstein, J. D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0790-07.2007 · Cited by 313
Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment
Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., et al. (2006) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00377.x · Cited by 282
Foran, E., & Trotti, D. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2444 · Cited by 268
Cudkowicz, M. E., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A., Brooks, B., Conwit, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70222-4 · Cited by 241
Astrocytic dysfunction: Insights on the role in neurodegeneration
Rossi, D., & Volterra, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.012 · Cited by 219
Takahashi, K., Foster, J. B., & Lin, C.-L. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1937-8 · Cited by 208
“Enhanced EAAT2 expression by genetic manipulation and pharmacological treatment in SOD1 mice has shown some beneficial effects [41, 56, 178].”
Bonafede, R., & Mariotti, R. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00080 · Cited by 204
“The loss of functional EAAT2 was also observed in affected brain regions of other neurodegenerative diseases, such as Alzheimer’s and Huntington’s diseases Frontiers in Cellular Neuroscience | www.frontiersin.org 4 March 2017 | Volume 11 | Article 80 (Guo et al., 2003).”
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Focal degeneration of astrocytes in amyotrophic lateral sclerosis
Rossi, D., Brambilla, L., Valori, C. F., Roncoroni, C., Crugnola, A., Yokota, T., Bredesen, D. E., & Volterra, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.99 · Cited by 194
Excitotoxicity and Amyotrophic Lateral Sclerosis
van Cutsem, P., Dewil, M., Robberecht, W., & van den Bosch, L. (2005) · Neurodegenerative Diseases · doi:10.1159/000089620 · Cited by 192
“: catalysis of H 2 O 2 by mutant SOD1 was shown to induce oxidative damage to the intracellular carboxyl-terminal part of EAAT2, resulting in decreased glutamate transport. It remains uncertain whether the loss of EAAT2 represents a primary mechanism in ALS and this is the subject of ongoing research. Crossbreeding EA…”
Olloquequi, J., Cornejo-Córdova, E., Verdaguer, E., Soriano, F. X., Binvignat, O., Auladell, C., & Camins, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754680 · Cited by 189
Rossi, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.04.003 · Cited by 177
The Complex Molecular Biology of Amyotrophic Lateral Sclerosis (ALS)
Redler, R. L., & Dokholyan, N. V. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00002-3 · Cited by 172
Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System
Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170
“Thus, overexpression of EAAT2 in SOD1 mutant mice was only partially protective [213].”
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
Turner, M. R., Bowser, R., Bruijn, L., Dupuis, L., Ludolph, A., McGrath, M., Manfredi, G., Maragakis, N., Miller, R. G., Pullman, S. L., et al. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.778554 · Cited by 168
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 164
“Overexpression of EAAT2 in mSOD1 G93A mice may be neuroprotective, delaying the onset of motor deficits and reducing activation of caspase-3, a potent promoter of apoptotic cell death pathways [43].”
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection
Kong, Q., Chang, L.-C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., Ibabao, B., Lin, Y., Stouffer, N., Mukhopadhyay, C. D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66163 · Cited by 156
Self-citationExpression Specificity of GFAP Transgenes
Su, M., Hu, H., Lee, Y., D’Azzo, A., Messing, A., & Brenner, M. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6881-1 · Cited by 124
The Role of the Microbiota–Gut–Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases
Obrenovich, M., Jaworski, H., Tadimalla, T., Mistry, A., Sykes, L., Perry, G., & Bonomo, R. (2020) · Microorganisms · doi:10.3390/microorganisms8050784 · Cited by 62
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Metadata
- Authors
- Guo, H.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2519-2532
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151927746
- Cited by
- 284
- References
- 48
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.